Cargando…
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527608/ https://www.ncbi.nlm.nih.gov/pubmed/35366308 http://dx.doi.org/10.1093/ibd/izac066 |
| _version_ | 1784801112469012480 |
|---|---|
| author | Zhang, Wenhui Scalori, Astrid Fuh, Franklin McBride, Jacqueline She, Gaohong Kierkus, Jaroslaw Korczowski, Bartosz Li, Regan Abouhossein, Mariam Kadva, Alysha Park, K T Tang, Meina Tao |
| author_facet | Zhang, Wenhui Scalori, Astrid Fuh, Franklin McBride, Jacqueline She, Gaohong Kierkus, Jaroslaw Korczowski, Bartosz Li, Regan Abouhossein, Mariam Kadva, Alysha Park, K T Tang, Meina Tao |
| author_sort | Zhang, Wenhui |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9527608 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95276082022-10-03 Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial Zhang, Wenhui Scalori, Astrid Fuh, Franklin McBride, Jacqueline She, Gaohong Kierkus, Jaroslaw Korczowski, Bartosz Li, Regan Abouhossein, Mariam Kadva, Alysha Park, K T Tang, Meina Tao Inflamm Bowel Dis Corrections Oxford University Press 2022-04-02 /pmc/articles/PMC9527608/ /pubmed/35366308 http://dx.doi.org/10.1093/ibd/izac066 Text en © 2022 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Corrections Zhang, Wenhui Scalori, Astrid Fuh, Franklin McBride, Jacqueline She, Gaohong Kierkus, Jaroslaw Korczowski, Bartosz Li, Regan Abouhossein, Mariam Kadva, Alysha Park, K T Tang, Meina Tao Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial |
| title | Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial |
| title_full | Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial |
| title_fullStr | Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial |
| title_full_unstemmed | Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial |
| title_short | Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial |
| title_sort | correction to: pharmacokinetics, pharmacodynamics, and safety of etrolizumab in children with moderately to severely active ulcerative colitis or crohn’s disease: results from a phase 1 randomized trial |
| topic | Corrections |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527608/ https://www.ncbi.nlm.nih.gov/pubmed/35366308 http://dx.doi.org/10.1093/ibd/izac066 |
| work_keys_str_mv | AT zhangwenhui correctiontopharmacokineticspharmacodynamicsandsafetyofetrolizumabinchildrenwithmoderatelytoseverelyactiveulcerativecolitisorcrohnsdiseaseresultsfromaphase1randomizedtrial AT scaloriastrid correctiontopharmacokineticspharmacodynamicsandsafetyofetrolizumabinchildrenwithmoderatelytoseverelyactiveulcerativecolitisorcrohnsdiseaseresultsfromaphase1randomizedtrial AT fuhfranklin correctiontopharmacokineticspharmacodynamicsandsafetyofetrolizumabinchildrenwithmoderatelytoseverelyactiveulcerativecolitisorcrohnsdiseaseresultsfromaphase1randomizedtrial AT mcbridejacqueline correctiontopharmacokineticspharmacodynamicsandsafetyofetrolizumabinchildrenwithmoderatelytoseverelyactiveulcerativecolitisorcrohnsdiseaseresultsfromaphase1randomizedtrial AT shegaohong correctiontopharmacokineticspharmacodynamicsandsafetyofetrolizumabinchildrenwithmoderatelytoseverelyactiveulcerativecolitisorcrohnsdiseaseresultsfromaphase1randomizedtrial AT kierkusjaroslaw correctiontopharmacokineticspharmacodynamicsandsafetyofetrolizumabinchildrenwithmoderatelytoseverelyactiveulcerativecolitisorcrohnsdiseaseresultsfromaphase1randomizedtrial AT korczowskibartosz correctiontopharmacokineticspharmacodynamicsandsafetyofetrolizumabinchildrenwithmoderatelytoseverelyactiveulcerativecolitisorcrohnsdiseaseresultsfromaphase1randomizedtrial AT liregan correctiontopharmacokineticspharmacodynamicsandsafetyofetrolizumabinchildrenwithmoderatelytoseverelyactiveulcerativecolitisorcrohnsdiseaseresultsfromaphase1randomizedtrial AT abouhosseinmariam correctiontopharmacokineticspharmacodynamicsandsafetyofetrolizumabinchildrenwithmoderatelytoseverelyactiveulcerativecolitisorcrohnsdiseaseresultsfromaphase1randomizedtrial AT kadvaalysha correctiontopharmacokineticspharmacodynamicsandsafetyofetrolizumabinchildrenwithmoderatelytoseverelyactiveulcerativecolitisorcrohnsdiseaseresultsfromaphase1randomizedtrial AT parkkt correctiontopharmacokineticspharmacodynamicsandsafetyofetrolizumabinchildrenwithmoderatelytoseverelyactiveulcerativecolitisorcrohnsdiseaseresultsfromaphase1randomizedtrial AT tangmeinatao correctiontopharmacokineticspharmacodynamicsandsafetyofetrolizumabinchildrenwithmoderatelytoseverelyactiveulcerativecolitisorcrohnsdiseaseresultsfromaphase1randomizedtrial |